We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01517776
Recruitment Status : Terminated (due to an altered benefit/risk assessment.)
First Posted : January 25, 2012
Last Update Posted : July 21, 2015
Sponsor:
Collaborator:
Merck KGaA
Information provided by (Responsible Party):
Christof Kramm, Martin-Luther-Universität Halle-Wittenberg

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : March 2014
  Study Completion Date : April 2014
  Certification or Request for Extension to Delay Results Submission: May 26, 2015